NBIX vs. RGEN, EXEL, HALO, DNLI, ADPT, BIIB, QGEN, PCVX, RVMD, and BNTX
Should you be buying Neurocrine Biosciences stock or one of its competitors? The main competitors of Neurocrine Biosciences include Repligen (RGEN), Exelixis (EXEL), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Adaptive Biotechnologies (ADPT), Biogen (BIIB), Qiagen (QGEN), Vaxcyte (PCVX), Revolution Medicines (RVMD), and BioNTech (BNTX). These companies are all part of the "biological products, except diagnostic" industry.
Repligen (NASDAQ:RGEN) and Neurocrine Biosciences (NASDAQ:NBIX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings, community ranking and dividends.
97.6% of Repligen shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 1.2% of Repligen shares are held by insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Repligen currently has a consensus price target of $197.75, suggesting a potential upside of 18.90%. Neurocrine Biosciences has a consensus price target of $147.46, suggesting a potential upside of 5.46%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Repligen is more favorable than Neurocrine Biosciences.
Neurocrine Biosciences received 580 more outperform votes than Repligen when rated by MarketBeat users. Likewise, 77.61% of users gave Neurocrine Biosciences an outperform vote while only 68.08% of users gave Repligen an outperform vote.
Repligen has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500.
Neurocrine Biosciences has a net margin of 13.23% compared to Neurocrine Biosciences' net margin of 6.51%. Repligen's return on equity of 12.85% beat Neurocrine Biosciences' return on equity.
In the previous week, Neurocrine Biosciences had 22 more articles in the media than Repligen. MarketBeat recorded 37 mentions for Neurocrine Biosciences and 15 mentions for Repligen. Repligen's average media sentiment score of 0.77 beat Neurocrine Biosciences' score of -0.30 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.
Neurocrine Biosciences has higher revenue and earnings than Repligen. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.
Summary
Neurocrine Biosciences beats Repligen on 12 of the 18 factors compared between the two stocks.
Get Neurocrine Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NBIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neurocrine Biosciences Competitors List
Related Companies and Tools
